IP Library › Granted Patent US 12,460,151
Granted Patent B2
US 12,460,151 · App. 18/504,863 · Granted Nov 4, 2025

Polypeptides having phospholipase C activity and polynucleotides encoding same

Inventors: Dorotea Raventos Segura (Rungsted, DK); Robert Piotr Olinski (Vaerlose, DK); Kim Borch (Birkerod, DK); Allan Noergaard (Lyngby, DK); Jesper Brask (Vaerlose, DK); Rune Falkenberg Haller (Roskilde, DK); Marianne Linde Damstrup (Gentofte, DK)
Assignee: Novozymes A/S
C11B3/003C12N9/16C12N9/20C12P7/6445C12Y301/04003C12Y301/04011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,460,151
App. No.
18/504,863
Granted
Nov 4, 2025
Kind
B2
Abstract

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Claims (31)

1 . A composition comprising

(a) a phosphatidylinositol phospholipase C having at least 90% sequence identity to amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3; and

(b) a phosphatidylcholine and phosphatidylethanolamine-specific phospholipase C polypeptide (“a PC and PE-specific phospholipase C”) having at least 90% sequence identity to amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

2 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C has at least 95% sequence identity to amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3.

3 . The composition of claim 1 , wherein

(b) the PC and PE-specific phospholipase C has at least 95% sequence identity to amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

4 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C has at least 95% sequence identity to amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3; and

(b) the PC and PE-specific phospholipase C has at least 95% sequence identity to amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

5 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C has at least 98% sequence identity to amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3.

6 . The composition of claim 1 , wherein

(b) the PC and PE-specific phospholipase C has at least 98% sequence identity to amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

7 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C has at least 98% sequence identity to amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3; and

(b) the PC and PE-specific phospholipase C has at least 98% sequence identity to amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

8 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C comprises amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3.

9 . The composition of claim 1 , wherein

(b) the PC and PE-specific phospholipase C polypeptide comprises amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

10 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C comprises amino acid residues 26-322 of SEQ ID NO: 2 or amino acid residues 1-298 of SEQ ID NO: 3; and

(b) the PC and PE-specific phospholipase C polypeptide comprises amino acid residues 25-280 of SEQ ID NO: 38 or amino acid residues 36-280 of SEQ ID NO: 38.

11 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C is a fragment of amino acid residues 26-322 of SEQ ID NO: 2 or a fragment of amino acid residues 1-298 of SEQ ID NO: 3.

12 . The composition of claim 1 , wherein

(b) the phosphatidylcholine (“PC”) and phosphatidylethanolamine (“PE”)-specific phospholipase C polypeptide is a fragment of amino acid residues 39-283 of SEQ ID NO: 22.

13 . The composition of claim 1 , wherein

(a) the phosphatidylinositol phospholipase C is a fragment of amino acid residues 26-322 of SEQ ID NO: 2 or a fragment of amino acid residues 1-298 of SEQ ID NO: 3; and

(b) the phosphatidylcholine (“PC”) and phosphatidylethanolamine (“PE”)-specific phospholipase C polypeptide is a fragment of amino acid residues 39-283 of SEQ ID NO: 22.

Priority Claims (1)
EP 14160698 · Mar 19, 2014 · regional
Continuity (4)
Division 17177349 · Feb 17, 2021
Division 16423748 · May 28, 2019
Division 15126098
Related Publication 20240158718A1 · May 16, 2024
References Cited (29)
US 10351795B2 · Segura · 2019 [cited by examiner]
US 10954469B2 · Segura · 2021 [cited by applicant]
US 20080182322A1 · Dayton · 2008 [cited by applicant]
US 20130011887A1 · Dayton et al. · 2013 [cited by applicant]
US 20130309751A1 · Tang et al. · 2013 [cited by applicant]
US 20140371476A1 · Dayton · 2014 [cited by applicant]
US 20190284503A1 · Segura · 2019 [cited by applicant]
CN 101663382 · 2010 [cited by applicant]
CN 102575243A · 2012 [cited by applicant]
CN 103314091A · 2013 [cited by applicant]
WO 2003089620A2 · 2003 [cited by applicant]
WO 2007059927A1 · 2007 [cited by applicant]
WO 2008094847A1 · 2008 [cited by applicant]
WO 2011046815A1 · 2011 [cited by applicant]
WO 2012062817A1 · 2012 [cited by applicant]
WO 2015173426A1 · 2015 [cited by applicant]
Anonymous, NCBI References No. WP_006093549.1 (2013). [cited by applicant]
Anonymous, NCBI Reference No. WP_009046168.1 (2013). [cited by applicant]
Anonymous, NCBI Reference No. WP_015637460.1 (2013). [cited by applicant]
Clausen, Eur. J. Lipid Sci. Technol., vol. 103, pp. 333-340 (2001). [cited by applicant]
Dijkstra, 101st AOCS Annual Meeting & Expo, p. 23 (May 16-19, 2010). [cited by applicant]
Dijkstra, Eur. J. Lipid Sci. Technol., vol. 112, pp. 1178-1189 (2010). [cited by applicant]
Feldgarden et al., UniProt Accession No. J8N0F4 (2012). [cited by applicant]
Gavrilenko et al., GenBank Accesion No. CAA45501.1 (1993). [cited by applicant]
Kostadinova et al., Biotechnol. & Biotechnol. Eq., vol. 11, No. 3. pp. 22-27 (1997). [cited by applicant]
Paulsen et al., UniProt Accession No. Q4K3U9 (2005). [cited by applicant]
Peters et al., The Plant Cell, vol. 22, No. 8, pp. 2642-2659 (2010). [cited by applicant]
Vasconcellos et al., UniProt Accession No. U6ZX29 (2014). [cited by applicant]
Cai et al., 2012, Uniprot Accession No. I8AFV4. [cited by applicant]